Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 60 results

Filters: First Letter Of Last Name is M [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

I

Ma C, Sedano R, Almradi A, Casteele NVande, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R et al.. 2021. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials.. Gastroenterology. 160(7):2291-2302.

Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. 2019. Innovations in Oral Therapies for Inflammatory Bowel Disease.. Drugs. 79(12):1321-1335.

Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW. 2012. Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease.. PLoS One. 7(7):e41594.

Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al.. 2020. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.

Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al.. 2020. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.

Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Casteele NVande, Boland BS, Prokop L et al.. 2020. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.. Am J Gastroenterol. 115(6):885-894.

Steinlauf AF, Marion JF, Sacchar D, Sandler AL, Greenstein AJ, Harris MT. 2011. Ileouterine fistulae: possible predisposing factors to this rare complication of Crohn's disease.. Inflamm Bowel Dis. 17(3):872-3.

Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A et al.. 2017. IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.. Sci Transl Med. 9(376)

E

Gogokhia L, Buhrke K, Bell R, Hoffman B, D Brown G, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF et al.. 2019. Expansion of Bacteriophages Is Linked to Aggravated Intestinal Inflammation and Colitis.. Cell Host Microbe. 25(2):285-299.e8.

Lukin DJ, Lawlor G, Hudesman DP, Durbin L, Axelrad JE, Passi M, Cavaliere K, Coburn E, Loftus M, Jen H et al.. 2019. Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile.. Inflamm Bowel Dis. 25(4):775-781.

Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel J-F, Lewis JD, Ghosh S et al.. 2020. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.. Gastroenterology. 158(8):2123-2138.e8.

D

Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J et al.. 2021. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.. Lancet Gastroenterol Hepatol. 6(10):826-849.

Dulai PS, Singh S, Casteele NVande, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A et al.. 2020. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis.. Clin Gastroenterol Hepatol. 18(13):2952-2961.e8.

Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P et al.. 2018. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease.. Gastroenterology. 155(3):687-695.e10.

Cohen-Mekelburg S, Gold S, Schneider Y, Dennis M, Oromendia C, Yeo H, Michelassi F, Scherl E, Steinlauf A. 2019. Delays in Initiating Post-operative Prophylactic Biologic Therapy Are Common Among Crohn's Disease Patients.. Dig Dis Sci. 64(1):196-203.

Kumar A, Lukin D, Battat R, Schwartzman M, Mandl LA, Scherl E, Longman RS. 2020. Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis.. J Gastroenterol. 55(7):667-678.

C

Longman RS, Diehl GE, Victorio DA, Huh JR, Galan C, Miraldi ER, Swaminath A, Bonneau R, Scherl EJ, Littman DR. 2014. CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.. J Exp Med. 211(8):1571-83.

Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SGuk et al.. 2007. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum.. ISME J. 1(5):403-18.

Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS. 2010. Crohn's disease is associated with restless legs syndrome.. Inflamm Bowel Dis. 16(2):275-9.

Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS. 2010. Crohn's disease is associated with restless legs syndrome.. Inflamm Bowel Dis. 16(2):275-9.

Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al.. 2015. Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.

Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al.. 2015. Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.

Chen HJoyce, Sun J, Huang Z, Hou H, Arcilla M, Rakhilin N, Joe DJ, Choi J, Gadamsetty P, Milsom J et al.. 2015. Comprehensive models of human primary and metastatic colorectal tumors in immunodeficient and immunocompetent mice by chemokine targeting.. Nat Biotechnol. 33(6):656-60.

Kumar A, Teslova T, Taub E, Miller JD, Lukin DJ. 2020. Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications.. Dig Dis Sci.

Marion JF, Waye JD, Present DH, Israel Y, Bodian C, Harpaz N, Chapman M, Itzkowitz S, Steinlauf AF, Abreu MT et al.. 2008. Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial.. Am J Gastroenterol. 103(9):2342-9.